Fig. 2: SMC-specific ADAR1 is required to maintain vascular integrity and survival.

a, Schematic of the SMC-Adar−/− model and accumulation of dsRNA and MDA5 activation. b, Survival curves for 56 mice treated with tamoxifen at 8 weeks of age (n = 15 control, n = 21 SMC-Adar−/+, n = 20 SMC-Adar−/−), comparing SMC-Adar−/−, SMC-Adar−/+ (Adarfl/WT; Myh11CreERT2; RosatdTomato; Apoe−/−) and control (AdarWT/WT; Myh11CreERT2; RosatdTomato; Apoe−/−) genotypes. c, Gross image of the aortic root and ascending aorta of an SMC-Adar−/− mouse at 2 weeks following tamoxifen treatment. d,e, Representative images of hematoxylin and eosin (H&E) staining from SMC-Adar−/− (d) and control genotype mice (e). f,g, Fluorescence imaging with autofluorescence (Auto) indicating elastin (green) and MYH11-derived cells labeled with tdTomato (red) in two SMC-Adar−/− mice with adventitial ballooning. h, Brightfield imaging of an aorta cross-section from an SMC-Adar−/− mouse corresponding to fluorescence imaging in g. i, CD68 immunostaining of an aorta cross-section from an SMC-Adar−/− mouse showing macrophage infiltration. j, Masson trichrome stain of an aorta cross-section from an SMC-Adar−/− mouse showing intramedial collagen deposition. The P value represents comparison of survival curves by log-rank (Mantel–Cox) test (b).